|Over a week ago|
Fly Intel: Top five analyst downgrades » 09:5509/1009/10/21
CFX, SUMO, FCX, HGEN, CI
Catch up on today's…
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Colfax (CFX) downgraded to Neutral from Buy at Goldman Sachs with analyst Joe Ritchie saying his estimates are no longer differentiated versus consensus and that he sees less potential for the stock to re-rate at this point in the cycle. 2. Sumo Logic (SUMO) downgraded to Neutral from Buy at BTIG with analyst Gray Powell saying the company's Q2 results were "solid" with 29% headline billings growth topping his 25% estimate, and the management increased its total revenue guidance by about 1%, but some underlying trends were concerning as revenue upside in the full-year outlook was driven entirely by improved trends at Sumo's largest customer. 3. Freeport McMoRan (FCX) downgraded to Underperform from Neutral at Credit Suisse with analyst Curt Woodworth saying copper prices are more a reflection of future inflation expectations than a real-time gauge of the health of the global economy, Woodworth tells investors in a research note and adding he is concerned that the market is "overly bullish" on the medium term demand uptake from electric vehicles and renewables. 4. Humanigen (HGEN) downgraded to Hold from Buy at Jefferies with analyst Kelly Shi noting that the FDA invited Humanigen to submit additional data after denying its EUA request. 5. Cigna (CI) downgraded to Underperform from Buy at BofA with analyst Kevin Fischbeck saying while the company has now integrated Express Scripts successfully, de-levered, and sold off underperforming units, the growth outlook from here is "less clear" and he sees lower visibility in its earnings trajectory over the next couple of years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Colfax downgraded to Neutral from Buy at Goldman Sachs » 04:5409/1009/10/21
Goldman Sachs analyst Joe…
Goldman Sachs analyst Joe Ritchie downgraded Colfax to Neutral from Buy with a price target of $51, down from $53. The analyst says his estimates are no longer differentiated versus consensus and that he sees less potential for the stock to re-rate at this point in the cycle. The stock has outperformed year-to-date and it's hard to argue for multiple re-rating here given the early cycle nature of both segments and the free cash flow characteristics, Ritchie tells investors in a research note.
|Over a month ago|
Colfax price target raised to $56 from $50 at Argus » 08:1708/1608/16/21
Argus analyst John Eade…
Argus analyst John Eade raised the firm's price target on Colfax to $56 from $50 and keeps a Buy rating on the shares. The analyst sees the company as a "well-managed" mid-cap company with a new focus on med-tech. Colfax's 2020 earnings were weak due to the impact of the coronavirus, but results have been improving quarter to quarter, and the recent healthcare company acquisitions should build momentum, Eade tells investors in a research note.
Colfax 6.54M share Spot Secondary priced at $43.90 » 06:4607/2907/29/21
The deal range was…
The deal range was $43.88-$44.88. Morgan Stanley acted as sole book running manager for the offering.
Colfax announces offering of 6.54M shares of common stock for holders » 16:3807/2807/28/21
Colfax Corporation announced that certain of its stockholders have commenced an underwritten secondary offering of 6.54M shares of the company's common stock. Morgan Stanley is acting as sole book-running manager for the offering.
Colfax raises FY21 EPS view to $2.10-$2.20, consensus $2.15 16:3807/2807/28/21
Colfax sees Q3 EPS 50c-55c , consensus 56c 16:3607/2807/28/21
Colfax reports Q2 EPS 56c, consensus 53c » 16:3507/2807/28/21
Reports Q2 revenue…
Reports Q2 revenue $985.9M, consensus $917.93M.
|Over a quarter ago|
Colfax raises FY21 adjusted EPS view to $2.05-$2.15 from $2.00-$2.15 » 06:0904/2904/29/21
FY21 consensus $2.12.…
FY21 consensus $2.12. Cites the strength of first quarter results.
Colfax sees Q2 adjusted EPS 48c-53c, consensus 53c 06:0804/2904/29/21